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Expression in a recombinant system has been difficult to obtain for any of the major fibrillar collagens
that require processing by eight or more post-translational enzymes. Here, two DNA constructs were designed so that the promoter region of the gene for the
pro-cYl(1) chain of human type I procollagen drove
expression of the human type I1 procollagen gene in
mouseNIH 3T3 cells, a culture line that normally
synthesizes type I procollagen but not any cartilagespecific protein such as type I1 procollagen. Both constructs were expressed as both mRNA and protein. In
clonesexpressing the construct at high levels, the
steady-state levelsof mRNAand the productionof type
I1 procollagen were comparable to the mRNA levels
and production oftype I procollagen from the endogenous mouse genes. Comparison of clones containing the
two constructs demonstrated that sequences extending
80 base pairs beyond the major polyadenylation signal
of the gene are not in themselves sufficient for correct
termination and 3‘ processing of RNAtranscripts. The
results strongly suggest that specific sequences present
in a downstream 3.5-kilobase SphIISphI fragment determine the termination of the transcription. Of special
importance is that the system will make it possible to
examine the consequences of mutations in the human
type I1 procollagen gene on the processing ofRNA
transcripts and on the functional properties of the protein simply by using the genomic DNA from leukocytes
or other non-cartilaginous sources.

has not been reportedfor any of the major fibrillar collagens
that require processing by eight or more post-translational
enzymes (1).Rescue experiments in cells that synthesized
only one of the two chains for type I procollagen were successful in two differentsystems (2, 3), but synthesis of a
procollagen molecule in whichall three chains are derived
from an exogenous gene has not been obtained. Failure to
obtain expression of genes for fibrillar collagens
in a fully
recombinantsystemhashamperedattemptstostudythe
normal structure-function relationships of the proteins and
to study theeffects of mutations. In particular, mutations in
the gene for type I1 procollagen have recently been implicated
as the cause of several human diseases (4-13),but because
adequate numbers of human cartilage cells are difficult to
obtain and because human chondrocytes readily lose their
the causal relationshipbetween
phenotype in culture (14, 15),
a mutation in the gene and the biological function of the
protein has proven elusive. Here we describea systemin
which it is possible to express the human type
I1 procollagen
gene in stable transfectants of mouse NIH 3T3 cells. The
results also indicate that correct termination and3’ processing of RNA transcripts of the gene require sequences over 80
bp’ downstream of the major polyadenylation signal (16).
MATERIALSANDMETHODS

Gene Constructs-Two versions of a cosmid construct were prepared. Both contained a 5”fragment from the human COLlAl gene
that included the promoter, the first exon, most
and of the first intron
(Fig. 1). The 5”fragment extended from -500 to +1445 bp of the
gene (17-19). Both constructs also contained two SphIISphI fragments of 14 and 12 kb of the human COL2A1 gene (20-27). The 5’end of the 14-kb fragment corresponded to the 3’-end of intron 1B
(28), and the 3’-end of the 12-kb fragment extended 80 bp beyond
the major polyadenylationsignal of the gene. One construct differed
from the other in that it contained an additional 3.5-kb SphIISphI
fragment from the 3’-endof the gene.
The first construct was assembled from three fragments: ( a ) a 2kb SphIIHindIII fragment from the 5’-end of human COLlAl gene
in which the SphI site was converted to a SalI site and the Hind111
site was converted to an SphI site; ( b ) a 14-kb SphIISphI fragment
from the middle of the human COL2Al gene; and (c) a 12-kb SphI/
SphI fragment that extended
80 bp beyond the major polyadenylation
signal of the human COL2Al gene and in which the 3’-SphI sitewas
converted toa SalI site.The three fragmentswere assembled by fourway ligation into the SalI site of the cosmid vector pJB8 that was
previously modified by insertion of a 7-kb EcoRIIEcoRI stuffer fragment (27).
The second construct was assembled in two steps. The first step
involved (a) the 5”fragment from the COLlAl gene with SalIISphI
terminal sites used for the first construct and( b ) a 3.5-kb SphIISphI
fragment
extendedbeyond the 3’-end of the COLZA1 gene. The
Expression of many exogenous genes is readily obtained in 3’-SphI sitethat
in the 3.5-kb SphIISphI fragment was converted to a
a variety of recombinant host-vector systems. Expression of SalI site. In the first step, the 2-kh SalIISphI and 3.5-kb SphIISalI
a n exogenous gene, however,
is difficult to obtainif the protein fragments were assembled into the modified cosmid vector by threenormally requires extensive post-translational
processing. Ap- way ligation. In the second step the two SphIISphI fragments of 14
parently for this reason, expression in a recombinant system and 12 kb from the COL2Algene were inserted by three-way ligation
into the SphI siteof the construct obtainedin the first step.
Cell Transfections-For the cell transfection experiments,a cosmid
* This work was supported in part
by National Institutesof Health
Grants AR38188 and AR39740, by a grant from the March of Dimes clone containing a chimeric COLlAl/COL2Algene was cleaved with
Birth Defects Foundation, andby a grant from theLucille P. Markey SalI. A plasmid containing a neomycin-resistent gene (29) was lineCharitable Trust.The costsof publication of this articlewere defrayed arized by cleavage with BamHI. The two samples were mixed in a
in part by the payment of page charges. This article must therefore
be hereby marked“aduertisement”inaccordancewith
18 U.S.C.
The abbreviations usedare:bp,base
pair(s); kb, kilobase(s);
Section 1734 solely to indicate this fact.
COLlAl, gene for the pro-al(1) chainof type I procollagen; COLZA1,
11 To whom correspondence should be addressed.Tel.: 215-955- gene for the pro-al(I1) chain of type I1 procollagen; SDS, sodium
4830; Fax: 215-955-5393.
dodecyl sulfate.
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ratio of 1O:l of chimeric gene construct to neomycin-resistant gene,
and the mixture was then used for co-transfection of NIH 3T3 cells
t)v calcium phosphate precipitation (30). The DNA in the calcium
phosphate solution was layered onto cultured cells with ahout 10 p g
o f chimeric gene construct per 90-mm plate of preconfluent cells. The
cells were inruhated in Dulhecco's modified Eagle's medium containing 10% newhorn calf serum for 10 h. The samples were subjected to
glycerol shock hv adding a 15% glycerol solution for 3 min. The cells
were transferred to Ihlhecco's modified Eagle's medium cont.aining
10% newhorn calf serum for 24 h and then to the same
medium
containing 450 pg/ml C.418. Incubation in the medium containing
G418 was continued for ahout 4 weeks with a changeof medium every
third dav. The C418-resistant cellswere either pooled or used to
obtain clones hy isolating foci with a plastic cylinder and subculturing. FIG. 1. DNA constructs for expression of thehuman type I1
Northrrn Mot and Wrstrrn Hot Anal,v.&-Total RNAwas exprocollagen gene.The 7-kh k,'coIil stuffer was from the human t>Fe
tracted from stahlvtransfectedNIH
3T3 cellswith guanidinium
I 1 procollagengene (22, 27). The fhrrr arrolcv indicatethethree
isothiocyanateandthe RNA purified hv centrifugation in cesium
polyadenylation signals AATAAA. ATTAAA (the major signal in the
chloride (30).The RNA samples were separated hv agarose gel elecCOL2AI gene), and AATAAA, respectively. As indicated i n the text,
trophoresis and hlotted onto
nitrocellulose filters for hvhridization
two constructswere prepared. One contained the 3.5-kh:I'-.YphI/.Sn\I
with human cDNAs for COL2A1 (31) and COLIAl (32).
fragment, and the other
lacked the 3.5-kh fragment. W. prrmoter.
For Western hlot analysis. the culturemedium from each of several exon 1, and intron
1 of COLIAl gene: 0. intrnn 113 t o exon 5 2 of
clones was removed and separately precipitated hy the addition of
COLZA1 gene; W, 3.5-kh :1'-end of C012A1 gene; El. plR8 rosmid
were
solid ammoniumsulfate ( 3 0 5 saturation).Theprecipitates
vector: 0,7-kh k,'coRI.
collected hy centrifugation at 14,000 X g and then dialvzed against a
h f f e r containing 0.15 M NaCI, 0.5 mM EDTA, 0.5 mM N-ethylmaleimide. 0.1 mM p-aminohenzamidine, and 50 mM Tris-HCI (pH 7.4
A
B
C
a t 4 "C). Aliquots of the samples were heated to 100 "C for 5 min in
c
1
2
3
c
1
2
3
c
1
2
17;) SDS, 50 mM dithiothreitol, and 10% (v/v)glycerol, and separated
hv electrophoresis on 6%polyacrylamide gels on a mini-gel apparatus
(Holford SE250, Holford Scientific) at I25 V for 90 min. The separatedproteins were electrohlotted a t 4 0 V for 90 min from the
polyacrylamide gel onto
supported
a
nitrocellulose membrane
(Schleicher and Schuell). The transferred proteins were reacted for
30 min with a 1:500 dilution (v/v) of a polyclonal antibody specific
for the COOH-terminal telopeptide of human t.ype I1 collagen. The
antihodv was prepared in rahhits with a 23-residue synthetic peptide
thathadanamino
acid sequence found in theCOOH-terminal
telopeptide of human t-ype I1 collagen (22). The antibody did not
react by Western hlot analysis with chains of human t.ype I procolIagen, human type I collagen, human type I11 procollagen, or murine
with the
tvpe I procollagen. Theproteinsonthefilterreacting
antihodv were detected with a secondary anti-rahhit IgG antihodv
FIG. 2. Northern blot analysis of mRNA from control and
coupled to alkaline phosphatase (Promega Riotec) for 30 min. The
alkaline phosphatase was visualized with NRT/RCIP (Promega Rio- transfected cells. ['and A , control RNA from human fetal chontlrocytes (C) (31) and RNA from three cell lines transfected with the
tec) as directed hv the manufacturer.
longer gene construct (Fig. 1). The filter was hvhridized with a human
C'ynnogrn Nromidr Prptidr Anal-vsis of T.vpr I I Col/agrn-Pooled
C01,2A1 cDNA (31). I'anrl R. same RNA as in p o n d A hyhridized
samples of medium and cell laver of clones expressing the human
withahumanCOLIAl
cDNA ( 3 2 ) . I'nnrl (', control RNA from
COI2AI gene were digested at 15 "C wit.h 100 pg/ml pepsin at pH
human fetal chondrocytes and RNA from two clones containing the
2.0 for 5 h, and the proteinswere precipitated from the acidic solution
with 0.8 M NaCI. The pellets were collected hv centrifugation a t shorter gene construct (Fig. 1). The filter WAS hyhridizedwith the
14,000 X p for 30 min and resuspended in 0.15 M NaCl in 50 M Tris- samehuman COL2A1 cDNAas in panr/ A. The major hands of
HCI buffer, pH 7.4, at 4 "C. The proteins were then separated hy mRNAs in panrls A and R are about 5 and 5.8 kt).
polvarrvlamide gel electrophoresis in SDS and 6% polyacrylamide
pels as descrihed above. The gels were equilihrated with 70% (v/v)
formic acid for 10 min twice and digested with excess CNHr for 90 type I1 procollagen mRNA. The mRNAfrom cells containing
the construct that included the 3.5-kb SphIISphI fragment
lnin at 25 "C. The gels were placed perpendicularly to the direction
extending beyond the 3'-endof the gene appeared as a discrete
o f electrophoresis in the first dimension and electrophoresed in the
second dimension on polvacrylamide gels (6% stacking gel a n d 1 2 5 band of the expected size of about 5 kb(Fig. 2 A ) . I n contrast,
resolving gel) for 90 min. The separated peptides were electrohlotted the mRNA from cells containing the shorter construct (Fig.
onto nitrocellulose membranes for 60 min as described above. The
2C) appeared as a broad smear ranging
in size from RNAs
peptides were visualized hy reaction with rahhit polvclonal antihodies
I1 procollagen to
larger
than
the
expected
message
for
t-ype
that recognized multiple epitopes in human t.ypeI1 collagen. The
much smaller sizes. The results, therefore, demonstrated that
antihodies were generouslv provided hv Dr. Daniel Hartmann (Passequencesextending80
bp beyond theunusual A T T A A A
teur Institute,1,yon. France). The secondary antihodv
was anti-rahhit
IpC. coupled to alkaline phosphatase (Promega Hiotec).
major polvadenylation signal (16)of the gene are not in

themselvessufficient for correctterminationandthe
3'processing of RNA transcripts that is required to generate
region contains a GT-richsequence
The two gene constructs employed here (Fig. 1 ) were de- stable mRNA. The 80-bp
signed to test the hypothesis that the promoter
of the human (16) required for correct polyadenylation of transcripts of
COLlAl gene would drive expression of human COL2A1 gene most eukaryotic genes (33). To date, specific sequences that
in mouse NIH 3T3 cells that normally express type I procol- determine the terminat,ionof t.ranscription in eukaryotic cells
lagen but do not synthesize any
cartilage-specific proteins have not been defined (33). The results here strongly suggest
I1 procollagen. Theconstructs were used to that such specific sequences are present in the 3.5-kh S p h I /
suchastype
generate stably transfected cells, and the cells were assayed
SphI fragment of the human COL2A1 gene.
The transfected cells were then assayed for expregsion of
for synthesis of mRNA for human type I1 procollagen (Fig.
2). Cells transfected with either construct synthesized human thetype I1 procollagengene asprotein by Western blot
RESULTS ANDDISCUSSION

.
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analysis. For thispurpose, a polyclonal antibody was prepared
1st Dimension
in rabbits with a 23-residue synthetic peptide that had an
amino acid sequencefound in the COOH-terminal telopeptide
of human type I1 collagen (22). Western blots demonstrated
the presence of human pro-al(I1) chains in the media from
several stably transfected linesof 3T3 cells (Fig. 3). T o verify
that the transfected cell lines were synthesizing human type
I1 procollagen, two-dimensional cyanogen bromidepeptide
mapping was carried out(Fig. 4).The peptideswere identified
by Western blotting with polyclonal antibodies that reacted
with multiple epitopes in the triple helix of type I1 collagen.
T h e protein generated theexpected pattern of cyanogen bromide fragments for type I1 collagen.
The level of expression of the human COL2Al gene as
mRNA and proteinvaried in different lines and clones
of the
neomycin-resistant cells. In the highest expressing
clones, the
steady-state levels of mRNA for type I1 procollagen as assayed
with a cDNA for the human protein were comparable with
the endogenous levels of mRNA for mouse type I procollagen
A B C
as assayed with a cDNA for the human pro-al(1) chain. In
FIG. 4. CNBr peptide analysis of type I1 collagen. Pooled
the sameclones, the productionof human type I1 procollagen samples of medium and cell layer from clones expressing the human
t-ype I1 procollagen gene were pepsin-digested, salt-precipitated, and
was comparable with the production of endogenous mouse
separated by polyacrylamide gel electrophoresisin SDS. The gels
type I procollagen as assayed by semi-quantitative Western
blotting or by chromatographic purification of the proteins were digested with CNBr andelectrophoresed in a second dimension.
The peptides were electroblotted and visualized with polyclonal anfrom culture media (not shown). Ingeneral, there was a good tibodies that reacted with multiple epitopes in the triplehelix of type
correlation between the steady-statelevels of mRNA and the I1 collagen. For comparative purposes, only regions containing pepproduction of type I1 procollagen. Surprisingly, there were no tides from chains are shown. Lane A, control sample of type I1
consistent differences in levels of type I1 procollagen produc- collagen from human fetal chondrocytes; lanes B and C, samples from
two separateclones stably transfectedwith the shortergene construct
tion among clones transfected with the shorter construct and
cells transfected with thelonger construct containing the
3.5- shown in Fig. 1. The control sample also contained a small amount
of the 3n chainof type XI collagen.
kb SphIISphI fragment. The
longer and apparently less stable
transcripts from the shortergene constructs were, therefore,
efficiently translated. Clones producing high levels of type I1 mally express any cartilage gene. The results, therefore, are
procollagen were stable and continued to synthesize the pro- consistent withprevious reports suggesting that the promoter
with or without elements in the first intron is sufficient for
tein even after repeated passage in culture and storage as
tissue-specific expression of the COLlAlgene (34-38).
frozen cells over a 2-year period (not shown).
Of special importance is that the system developed here
The results here demonstrate that the promoter
region
together with the first exon and 1,218 bp of the first intron provides a unique method for obtaining human cartilage colof the human COLlAlgene are sufficient todrive expression lagen from stably transfected murine cells. Extensive efforts
of a cartilage-specific collagen gene in cells that do not nor- were made in the past to establish human chondrocytes that
continue to synthesize type I1 procollagen, but it is difficult
to expand the cultures withouta loss of phenotype (14, 15).
1
2
3
4
5
Also, it is usually difficult to obtain sufficient amounts of
human articular cartilage. These technical limitations have
presented serious obstacles in developing definitive data to
confirm observationssuggesting that mutationsin the typeI1
”
procollagen gene can cause several human diseases, including
chondrodysplasias (5-7), arthro-ophthalmopathy(Stickler
syndrome) (8-lo), and primary
generalized osteoarthritis (1113).The systemdeveloped here makes itpossible to generate
both mRNA and proteinsimply by using genomic DNA from
leukocytes or other non-cartilaginous sources. Therefore, it
makes itpossible to examine directly theeffects of mutations
in the human COL2Algene on the processing of RNA transcripts and on the functional properties
of type I1 procollagen.
(Y

FIG.3. Western blot analysis of proteinssynthesized by
individual clones expressing the human type I1 procollagen
gene. Proteins from culture media were reduced and separated by
polyacrylamide gel electrophoresis in SDS and were electroblotted
onto nitrocellulose filters. The filterswere reacted with the
polyclonal
rabbit antibodies to a 23-residue synthetic peptide (described in the
text) that were specific for human type I1 procollagen and collagen.
The secondary antibody was an anti-rabbit IgG linked to alkaline
phosphatase. Left lane, type I1 procollagen from human fetal chondrocytes (31). Lane 1 , control 3T3 cells that were not transfected;
lanes 2-5, clones of 3T3 cells transfected with the shorter construct
shown in Fig. 1.
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